Herpes Vaccine 2018 Research and Update
Progress of Herpes Cure Vaccine Research in 2018
Every new year brings new hope for scientists, doctors and those suffering from herpes. 2016 had some promising developments but none managed to reach any phase close to the expected resolution. 2017 was no different as many herpes cure vaccine research and development projects met abrupt ends without a definitive impact.
Global herpes cure vaccine research is interestingly poised at the absolute end of the year. 2018 may be more encouraging if some of the promising or potential solutions do end up being the vaccine that millions of people around the world need.
A Brief History of Herpes Cure Vaccine Research
Scientists and doctors have been trying to develop a vaccine for herpes for around a century. Dozens of potential solutions have been tested and while many were expected to be effective over the years, none had actually been proven to be an unquestionable cure.
Geneticists have focused on immune responses to prevent the outbreak of an infection or to contain the incubation of the virus while doctors have facilitated many tests on animals to gauge the effectiveness of different potential vaccines. Over the years and till date there have been the likes of HSV-2 ICP0‾ HSV-2 0ΔNLS, dl5-29 / ACAM-529 / HSV-529, Admedus HSV-2, Gen-003, HSV-2 ΔgD-2, HSV-2 Trivalent Vaccine and HerpV have been tested and there has been some observable impacts. Some of these candidates have managed to reduce viral shedding, some have managed to delay the onset of an outbreak but without resounding proof that it is not owing to any other factor and a few of these vaccines are no longer considered as a possible solution.
Setbacks in Herpes Cure Vaccine Research
GEN-003, a vaccine in development, is no longer in the race. Genocea had spent a lot of time and resources in this specific herpes cure vaccine research, which was supposed to be effective in controlling the symptoms of genital herpes and also cure it.
The company has officially stopped the herpes cure vaccine research. It hasn’t officially said that all herpes cure vaccine research have been stopped by the company but those who are aware of how these processes work and how companies plan their way forward will tell you that Genocea is unlikely to pursue a similar mission. If there is some positive development, either by chance or owing to the contributions of any noteworthy expert at the company, then the floodgates may open allowing money and resources into some new herpes cure vaccine research.
“The bottom line is that GEN-003 is dead…”
There is very little information available pertaining to the GV2207. It was widely known that Mymetics was working on some herpes cure vaccine research and that it was preparing for production and a controlled testing on animals but a whole year has gone by without anyone having any official update from the company.
It is safe to assume that like Mymetics, the various herpes cure vaccine research initiatives of Vitaherpavac & Herpovax, Zostavax and Tomegavax have also been far from any fruition. It should be noted that the herpes simplex virus has the ability to evade the human immune system. Scientists have flagged this as one of the most complex issues with the virus and which is why a vaccine is still elusive.
Glimmers of Hope
Chicken pox can be prevented with a vaccine and this has been offering the glimmer of hope for millions of people infected with the herpes simplex virus and doctors trying hard to find an irrefutable cure. Chicken pox and herpes simplex belong to the same family of viruses. While some researches and tests have failed to provide the much sought after answer, there are some developments that are encouraging. Till these developments lead to a more surefire outcome, those suffering from herpes will have to rely on Acyclovir or Zovirax, Famcyclovir or Famvir and Valacyclovir or Valtrex.
There are FDA approved ointments and pills that one can choose from. The side effects should be kept in mind as most drugs will have a few. This is fundamentally why herpes cure vaccine research has been such a long drawn process. Some potential solutions are absolutely safe but don’t have any desirable impact on the virus while some solutions do have some effect but are not impeccably safe.
One herpes cure vaccine research found evidence that vaccines created from different viruses can contain acute herpes simplex virus infections in mice. But the herpes cure vaccine research that most people are still hopeful about is the testing of a trivalent vaccine that can help the immune system to have three targets.
The trivalent vaccine was tested on guinea pigs and the findings were published in early 2017. There has been substantive development since at Perelman School of Medicine in Pennsylvania. Other herpes cure vaccine research and developments one must keep an eye out for are the clinical trials of HSV529 and VCL-HB01. The findings may not be published till the second quarter of 2018.
You may also like : Herpes Cure Secrets – Herpes Cure Options
Trivalent Sub-Unit Herpes Vaccine
All disappointed and many of them absolutely heartbroken at the failing of GEN-003 as a potential vaccine, have turned to the trivalent sub-unit herpes vaccine for hope. Dr. Harvey Friedman leads the herpes cure vaccine research at the University of Pennsylvania and he has gone on record to shed light on the most common questions of patients and doctors.
Dr. Friedman had published a paper in January in PLOS Pathogens where he had discussed how guinea pigs and rhesus monkeys responded to the trivalent herpes simplex virus vaccine at an immunological level. At this stage, the trivalent vaccine has the closest shot of being an actual cure, albeit no one knows what the near future has in store.
Dr. Friedman and his colleagues along with fellow researchers and experts have been working on various aspects of the trivalent herpes cure vaccine research. They have been developing and evaluating different animal models to understand the full scope of efficacy of the vaccine candidate. With the research and progress though the year 2017 at his disposal, Dr. Friedman is of the opinion that the trivalent sub-unit herpes vaccine will be able to generate a sufficient response from the immune system in animals to help them demand a clinical trial involving uninfected people. The first objective would be to help uninfected people remain uninfected, which is the goal of a vaccine. Prevention of genital herpes infection is the first step and then the objective of treating or curing the condition will become the obvious subsequent pursuit.
It is important to understand herpes vaccine is NOT a cure for the herpes virus
Dr. Friedman has been working on various animal models and he clearly states that they are not the definitive proof that should fuel expectations. Animal models help in fine tuning a vaccine which is then tweaked to suit different animals. It s not just about whether or not the vaccine will work but what exact composition will be effective, in what quantity and for whom. There are many variables and one has to work through all of them. The animal model used for guinea pigs is different from one used for mice.
The eventual approach to clinical trials meant for humans will be a world apart. Dr. Friedman has had reasons to be optimistic with the progresses his team has encountered and he has not been bogged down by the bombing of GEN-003. This is especially because he is confident using the right proteins and approaching the development of a vaccine in the right manner will yield the desired result.
Attenuated vs. Subunit Herpes Cure Vaccine Research
Dr. Friedman stated once that the impact of the trivalent subunit vaccine and the GEN-003 is similar in guinea pigs. Yet, the latter has been a failure. This is where the approach and the use of proteins become important. Dr. Friedman is also in favor of subunit vaccines and not attenuated vaccines.
Many proponents of live attenuated vaccines have been highlighting the enhanced efficacy. According to Friedman, live attenuated vaccines have more proteins compared with subunit vaccines. This helps live attenuated vaccines to be more effective in theory.
There is no case study specific to herpes cure vaccine research that indicates live attenuated vaccine is actually more effective than subunit vaccine. Even if one were to accept that, the risk of infection doesn’t make it worthwhile. Live attenuated vaccines have the slight likelihood of being more effective at the cost of safety. There is no chance of a subunit vaccine causing infection but there is a probability live attenuated vaccines would cause an infection.
The Near Future of Herpes Cure Vaccine Research
2018 may usher in some amazing developments, especially with the trivalent and similar vaccines. These are preventive vaccines and not exactly intended for treatment or cure. Prevention would still be an awesome development and it would help those infected to become immune to subsequent outbreaks or infections.
Herpes cure vaccine research is complicated and like all other such projects rather unpredictable. The developments in recent years have been more promising than seven to eight decades of progress put together. There is reason to be optimistic. Fortunately, there is a natural herpes cure to get rid of herpes forever. Discover The Best Herpes Cure Today!
Note: This Page was last updated on Wednesday 21st of February 2018